Latest News

At the 2026 New England Institute of Ambulatory Care Pharmacists (NEIAP) Annual Forum, Jennifer Goldman detailed how monitoring data drive engagement—and how a new dual sensor readies pharmacists for ketone alerts.

Phase 3 HARMONi-2 interim analysis shows first bispecific PD-1/VEGF antibody outperforming standard immunotherapy in first-line NSCLC.

Apitegromab-mstn is cleared as an add-on to SMN2-targeted treatment for patients aged 2 and older, directly addressing muscle loss.

With nearly 8 in 10 older adults misusing at least 1 OTC product, clearer counseling and labels could close the gap.

Phase 2 DeLLphi-309 data show comparable activity in previously treated SCLC with less frequent dosing.

The expanded approval of leniolisib makes it the first approved treatment for pediatric patients with activated phosphoinositide 3-kinase delta syndrome.

Carole R. Berini, PhD, and Saamir Pasha, MPH, of Ontada discuss a model designed to estimate missing baseline ECOG performance status in advanced prostate cancer and the validation needed before it can support broader real-world evidence research.

Contraceptive access gaps driven by federal rollbacks, provider shortages, and stalled state legislation could be narrowed by letting trained pharmacists prescribe birth control independently.

Cancer diagnoses among civilians exposed to 9/11 dust keep rising, with strained health programs struggling to meet growing needs.

With childhood immunization rates sliding and outbreaks accelerating, pharmacist-led counseling and vaccine administration can boost vaccination rates.

Once-daily oral deucrictibant extended-release significantly reduced hereditary angioedema attacks compared with placebo in the pivotal phase 3 CHAPTER-3 trial.

A Danish registry study found that COVID-19 infection was linked to a lower, not higher, risk of subsequent type 1 diabetes (T1D) in unvaccinated individuals younger than 30 years.

A high-dose vaccine cut hospitalizations for flu, pneumonia, and cardiorespiratory disease in older adults with asthma, COPD, and other chronic lung conditions.

The data support GPRC5D-directed CAR T-cell therapy as a potential option following prior BCMA-targeted treatment.

Investing in formalized technician education not only supports competency development but also strengthens workforce stability.

Student pharmacists have the unique position to encourage patient glucose monitoring through continuous glucose monitors (CGMs) and pilot initiatives to address provider, racial, and cost barriers.

The DAPA ACT HF-TIMI 68 analysis shows early, sustained congestion relief and rising diuretic efficiency through 2 months.

The FDA expanded the accelerated approval of sevabertinib to include treatment-naive adults with locally advanced or metastatic nonsquamous NSCLC harboring HER2 tyrosine kinase domain-activating mutations.

The investigational IL-33–targeting monoclonal antibody tozorakimab reduced moderate to severe COPD exacerbations across two phase 3 trials, including among patients with low blood eosinophil counts.

Health systems are being urged to reconcile inventory immediately, as the affected vials are commonly stocked for anaphylaxis and septic shock emergencies.

The phase 3 DeLLphi-305 trial found that the first-line maintenance therapy improved overall survival in extensive-stage small cell lung cancer (ES-SCLC) compared with durvalumab alone.